antibodies -online.com





Recombinant anti-VEGF (Bevacizumab Biosimilar) antibody



Go to Product page

()	۱ ۱		r١	/1		1 /	1
0	'V	ㄷ	I١	νı	\Box	٧	۷

Quantity:	1 mg
Target:	VEGF (Bevacizumab Biosimilar)
Reactivity:	Human
Host:	Mouse
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Conjugate:	This VEGF (Bevacizumab Biosimilar) antibody is un-conjugated
Application:	Flow Cytometry (FACS), In vivo Studies (in vivo)
Product Details	
Purpose:	Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody
Purpose: Immunogen:	The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar
•	· · · · · · · · · · · · · · · · · · ·
•	The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar
Immunogen:	The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line.
Immunogen: Isotype:	The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line. IgG1 kappa
Immunogen: Isotype: Specificity:	The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line. IgG1 kappa The monoclonal antibody Bevacizumab biosimilar specifically binds to the human VEGF-A.
Immunogen: Isotype: Specificity:	The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line. IgG1 kappa The monoclonal antibody Bevacizumab biosimilar specifically binds to the human VEGF-A. Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse
Immunogen: Isotype: Specificity: Characteristics:	The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line. IgG1 kappa The monoclonal antibody Bevacizumab biosimilar specifically binds to the human VEGF-A. Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.

Product Details Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method. **Target Details** Target: VEGF (Bevacizumab Biosimilar) Abstract: VEGF (Bevacizumab Biosimilar) Products Biosimilar Target Type: Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis Background: inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain. Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers. **Application Details Application Notes:** ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab. Restrictions: For Research Use only Handling Format: Liquid Concentration: 1 mg/mL Buffer: PBS, pH 7.4, no stabilizers or preservatives. Preservative: Without preservative Handling Advice: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. -20 °C Storage: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C Storage Comment:

as supplied.

12 months

Expiry Date: